Last reviewed · How we verify
NCT01624571
A Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel, Phase II Clinical Trial to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO in Patients Undergoing Colon Resection
Phase 2 trial testing LD02GIFRO in Colon Resection in 147 participants. Completed in 1 October 2012.
1 October 2012
Quick facts
| Lead sponsor | LG Life Sciences |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 147 |
| Start date | 1 March 2012 |
| Primary completion | 1 October 2012 |
| Estimated completion | 1 October 2012 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- LD02GIFRO — full drug profile →
Conditions studied
- Colon Resection — all drugs for Colon Resection →
- _large Interstinal Surgery — all drugs for _large Interstinal Surgery →
Sponsor
LG Life Sciences — full company profile →
Who can join
20 and older, any sex, with Colon Resection or _large Interstinal Surgery. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Improvement of gastrointestinal motility
Time frame: in hospitalization (Maximized 14 days)
Evaluation gastrointestinal function to the time of improvement gastrointestinal motility
Sponsor's own description
This clinical trial is conducted to determine the optimal dose of LD02GIFRO in improvement of gastrointestinal motility between each dose group by comparing the effectiveness and safety in patients undergoing colon resection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01624571
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colon Resection
Currently open trials in the same condition.
- NCT07083076 — Regular Diet Versus Extended Low Residue After Colon Surgery · NA · recruiting
Other LG Life Sciences trials
Trials by the same sponsor.
- NCT02831361 — Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in C · Phase 3 · completed
- NCT03015909 — Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. · Phase 4 · completed
- NCT02746380 — A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy · Phase 3 · completed
- NCT02290301 — An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01624571 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by LG Life Sciences
- Last refreshed: 26 February 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01624571.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing